# NCT06284486 (NCT06284486)

> A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

No report yet. It can be ordered.

- Drugs tested: revumenib plus venetoclax
- Indication: acute myeloid leukemia with MRD

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06284486
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Acute Myeloid Leukemia
- Interventions: Venetoclax; Revumenib
- Enrollment: 8
- Primary outcome: Safety and adverse events (AEs)

## Indexed commentary on NCT06284486 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06284486